AIM - AIM Immunotech to test Ampligen in mid-stage intranasal antiviral therapy trial

AIM ImmunoTech (AIM) has signed a contract to sponsor a Phase 2a Human Challenge Trial ((HCT)) to test the company’s drug Ampligen as a potential intranasal antiviral therapy using a human Rhinovirus hRV (common cold virus) and Influenza.The trial is expected to commence in Q4 2021.An HCT will allow AIM to expedite the development process for Ampligen by ensuring high infection rates for subjects who receive the drug, therefore also ensuring large data sets with potentially statistically significant results, the company said.Shares up more than 4% premarket.AIM had announced that all subjects have completed treatment in the company’s Phase 1 clinical study to assess the safety, tolerability and biological activity of ampligen as a potential intranasal therapy, last month.

For further details see:

AIM Immunotech to test Ampligen in mid-stage intranasal antiviral therapy trial